Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co‐formulation therapy twice‐daily with free combination of GLP‐1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co‐formulation therapy twice‐daily with free combination of GLP‐1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial

Published:2020-11-09 Issue:4 Volume:75 Page:
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Aso Yoshimasa¹^ORCID,Takada Yoshihisa²,Tomotsune Ken³,Chiba Yasuko⁴,Matsumura Mihoko⁵,Jojima Teruo¹,Sato Minoru⁶,Fujita Nobuya⁷,Kuroda Hisamoto⁸,Murano Shunichi⁹,Usui Isao¹

Affiliation:

1. Department of Endocrinology and Metabolism Dokkyo Medical University Mibu Tochigi Japan

2. Takada Clinic Tochigi Tochigi Japan

3. Saiseikai Utsunomiya Hospital Utsunomiya Tochigi Japan

4. Nagasaki Hospital Ashikaga Tochigi Japan

5. Kamitsuga General Hospital Kanuma Tochigi Japan

6. NHO Utsunomiya National Hospital Utsunomiya Tochigi Japan

7. Fujita Medical Clinic Utsunomiya Tochigi Japan

8. Green Clinic Mibu Tochigi Japan

9. Tochigi Medical Center Shimotsuga Tochigi Tochigi Japan

Publisher

Hindawi Limited

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.13734

Reference22 articles.

1. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

2. Individualizing Insulin Therapy in the Management of Type 2 Diabetes

3. Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs

4. Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

5. Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multidisciplinary Panel Consensus for the Management of Patients with Type 2 Diabetes: A Delphi Study;Archives of Medical Research;2024-01

2. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis;Frontiers in Endocrinology;2023-07-06

3. Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-Interventional Real-World Study;Journal of the ASEAN Federation of Endocrine Societies;2023-05-18

4. Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes;Diabetes, Obesity and Metabolism;2021-03-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3